Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Humanigen, Inc.
The purpose of Phase 1 is to determine a maximum tolerated dose (MTD) for KB004 when administered to subjects with hematologic malignancies who meet the entry criteria. Phase 1 has completed enrollment July of 2014, the recommended Phase 2 dose is 250 mg. AML 20 mg Cohort completed enrollment Dec 2014. The purpose of Phase 2 is to characterize preliminary clinical activity. The Phase 2 portion of the study consists of two parts: * Part A: Subjects with AML or MDS who meet the entry criteria * Part B: Subjects with MF who meet the entry criteria
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted